cdp 840 has been researched along with cilomilast in 6 studies
| Studies (cdp 840) | Trials (cdp 840) | Recent Studies (post-2010) (cdp 840) | Studies (cilomilast) | Trials (cilomilast) | Recent Studies (post-2010) (cilomilast) |
|---|---|---|---|---|---|
| 18 | 0 | 3 | 162 | 13 | 42 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andresen, CJ; Cheng, JB; Cohan, VL; Decker, C; DiCapua, FM; Duplantier, AJ; Johnson, KL; Kraus, KG; Turner, CR; UmLand, JP; Watson, JW; Wester, RT; Williams, AS; Williams, JA | 1 |
| Blouin, M; Brideau, C; Chan, CC; Chauret, N; Ducharme, Y; Girard, M; Girard, Y; Guay, D; Hamel, P; Huang, Z; Jones, TR; Laliberté, F; Masson, P; McAuliffe, M; Piechuta, H; Silva, J; Young, RN | 1 |
| Boss, H; Hatzelmann, A; Sterk, GJ; Timmerman, H; Van der Laan, IJ; Van der Mey, M | 1 |
| Boss, H; Couwenberg, D; Goubitz, K; Hatzelmann, A; Schenk, H; Sterk, GJ; Timmerman, H; Van der Mey, M | 1 |
| Blouin, M; Brideau, C; Chauret, N; Ducharme, Y; Frenette, R; Friesen, RW; Girard, Y; Hamel, P; Jones, TR; Laliberté, F; Li, C; Masson, P; McAuliffe, M | 1 |
| Jabaris, SS; Kodimuthali, A; Pal, M | 1 |
1 review(s) available for cdp 840 and cilomilast
| Article | Year |
|---|---|
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Topics: Asthma; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2008 |
5 other study(ies) available for cdp 840 and cilomilast
| Article | Year |
|---|---|
7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.
Topics: Airway Obstruction; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Bronchoalveolar Lavage Fluid; Cell Count; Cell Line; Cyclic AMP; Cytokines; Dihydropyridines; Drug Evaluation, Preclinical; Eosinophils; Guinea Pigs; Humans; In Vitro Techniques; Isoenzymes; Macaca fascicularis; Molecular Conformation; Neutrophils; Ovalbumin; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyrazoles; Pyrrolidinones; Rolipram; Structure-Activity Relationship | 1998 |
Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Animals; Bronchoconstriction; Cell Line, Transformed; Cyclic Nucleotide Phosphodiesterases, Type 4; Emetics; Ferrets; Guinea Pigs; Half-Life; Humans; Inhibitory Concentration 50; Ovalbumin; Phosphodiesterase Inhibitors; Pyridines; Rats; Recombinant Fusion Proteins; Saimiri; Sheep; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2002 |
Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adamantane; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cycloheptanes; Edema; Enzyme Inhibitors; Female; Humans; In Vitro Techniques; Leukocytes, Mononuclear; Lipopolysaccharides; Luminescent Measurements; Mice; Phthalazines; Reactive Oxygen Species; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2002 |
Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adamantane; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoates; Crystallography, X-Ray; Cyclic Nucleotide Phosphodiesterases, Type 4; Edema; Enzyme Inhibitors; Female; Humans; In Vitro Techniques; Mice; Molecular Conformation; Neutrophils; Phthalazines; Stereoisomerism; Structure-Activity Relationship | 2002 |
Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Alkylation; Animals; Biological Availability; Cell Line; Cyclic Nucleotide Phosphodiesterases, Type 4; Half-Life; Humans; Indicators and Reagents; Phosphodiesterase Inhibitors; Pyridines; Rats; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2002 |